Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers

Journal of Clinical Investigation(2025)10.1172/jci191781Source: DataRank Database

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers is a research paper published in Journal of Clinical Investigation (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.00)OA: goldTopics (65)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Jillian Greenberg,Tianyue Qin ORCID,Soo-Yeon Im,Gnana P. Krishnamoorthy ORCID,Laura Boucai ORCID

Live enrichment

PubMed:40828595 PMC:PMC12520682 OpenAlex:https://openalex.org/W4413325647

NIH

Grant: CA255211

NIH

Grant: CA249633

NIH

Grant: CA50706

NIH

Grant: CA255211,CA249633,CA50706

NCI NIH HHS

Grant: R01 CA249663

NCI NIH HHS

Grant: R01 CA255211

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: R01 CA050706

FWCI

0.00

Citation Percentile

0.1%

goldLicense: cc-by

journalhttp://www.jci.org/articles/view/191781/files/pdf

publisherhttp://www.jci.org/articles/view/191781/files/pdf

publisherhttps://www.jci.org/articles/view/191781/files/pdf

journalhttps://doi.org/10.1172/jci191781

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40828595

Fields of Study

Melanoma and MAPK PathwaysCytokine Signaling Pathways and InteractionsCancer Mechanisms and TherapyAnimalsProto-Oncogene Proteins B-rafThyroid Carcinoma, AnaplasticMiceProtein Kinase InhibitorsPyridonesHistocompatibility Antigens Class IIOximesCD4-Positive T-LymphocytesHumansThyroid NeoplasmsPyrimidinonesCell Line, TumorCD8-Positive T-LymphocytesImidazolesTrans-ActivatorsMutationNuclear ProteinsMice, KnockoutMAP Kinase Signaling SystemDrug Resistance, Neoplasm

MeSH Terms

AnimalsHistocompatibility Antigens Class IIHumansImidazolesMutationNuclear ProteinsOximesPyridonesPyrimidinonesThyroid NeoplasmsCD4-Positive T-LymphocytesTrans-ActivatorsMice, KnockoutCD8-Positive T-LymphocytesDrug Resistance, NeoplasmMAP Kinase Signaling SystemCell Line, TumorProtein Kinase InhibitorsProto-Oncogene Proteins B-rafMiceThyroid Carcinoma, Anaplastic

Keywords

Cancer researchAnaplastic thyroid cancerMutantMHC class IThyroidMHC class IIMAPK/ERK pathwayMedicineBiologyMajor histocompatibility complexInternal medicineImmunologyAntigenThyroid cancerSignal transductionCell biologyGeneticsCancerThyroid diseaseendocrinology

Sustainable Development Goals

SDG 0: Good health and well-being

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers

FAIR Checklist

Authors (17)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)